SE9502167L - Insulinanalog-kompositioner - Google Patents

Insulinanalog-kompositioner

Info

Publication number: SE9502167L
Authority: SE; Sweden
Prior art keywords: insulin analog; formulations; cresol; phenol; human insulin
Prior art date: 1994-06-16

Application number

SE9502167A

Other languages

Unknown language ( )

English (en)

Other versions

SE509052C2 (sv

SE9502167D0 (sv

Inventor

Diane Lee Bakaysa

David Nettleship Brems

Bruce Hill Frank

Henry Acken Havel

Allen Howard Pekar

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-16

Filing date

1995-06-14

Publication date

1995-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9502167(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-14 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1995-06-14 Publication of SE9502167D0 publication Critical patent/SE9502167D0/sv

1995-12-17 Publication of SE9502167L publication Critical patent/SE9502167L/sv

1998-11-30 Publication of SE509052C2 publication Critical patent/SE509052C2/sv

Links

239000000203 mixture Substances 0.000 title abstract 5
238000009472 formulation Methods 0.000 title abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
239000004026 insulin derivative Substances 0.000 title 1
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 3
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 2
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
238000010668 complexation reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE9502167A 1994-06-16 1995-06-14 Insulinanalog-hexamer-komplex SE509052C2 (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/260,634 US5474978A (en)	1994-06-16	1994-06-16	Insulin analog formulations

Publications (3)

Publication Number	Publication Date
SE9502167D0 SE9502167D0 (sv)	1995-06-14
SE9502167L true SE9502167L (sv)	1995-12-17
SE509052C2 SE509052C2 (sv)	1998-11-30

Family

ID=22989969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9502167A SE509052C2 (sv)	1994-06-16	1995-06-14	Insulinanalog-hexamer-komplex

Country Status (38)

Country	Link
US (1)	US5474978A (sv)
JP (2)	JP3171541B2 (sv)
KR (1)	KR100382326B1 (sv)
CN (1)	CN1105576C (sv)
AT (1)	AT408720B (sv)
BE (1)	BE1009408A5 (sv)
BR (1)	BR9502795A (sv)
CA (1)	CA2151560C (sv)
CH (2)	CH689250A5 (sv)
CO (1)	CO4410203A1 (sv)
CZ (1)	CZ287484B6 (sv)
DE (1)	DE19521720B4 (sv)
DK (1)	DK173015B1 (sv)
ES (1)	ES2091727B1 (sv)
FI (1)	FI118207B (sv)
FR (2)	FR2721214B1 (sv)
GB (1)	GB2291427B (sv)
GR (1)	GR1003004B (sv)
HU (1)	HU227240B1 (sv)
IE (1)	IE68853B1 (sv)
IL (1)	IL114151A (sv)
IT (1)	IT1276723B1 (sv)
LU (1)	LU88626A1 (sv)
MY (1)	MY115631A (sv)
NL (1)	NL1000566C2 (sv)
NO (1)	NO322128B1 (sv)
NZ (1)	NZ272359A (sv)
PE (1)	PE19496A1 (sv)
PL (1)	PL181310B1 (sv)
PT (1)	PT101722B (sv)
RO (1)	RO113530B1 (sv)
RS (1)	RS49577B (sv)
RU (1)	RU2152399C2 (sv)
SE (1)	SE509052C2 (sv)
SI (1)	SI9500200A (sv)
TW (1)	TW421596B (sv)
UA (1)	UA26874C2 (sv)
ZA (1)	ZA954943B (sv)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5836705A (en) *	1992-07-27	1998-11-17	Choate; John I. M.	Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5352050A (en) *	1992-07-27	1994-10-04	Choate John I M	Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5498088A (en) *	1992-07-27	1996-03-12	Choate; John I. M.	Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
DK72793D0 (da) *	1993-06-21	1993-06-21	Novo Nordisk As	Nyt produkt
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5547929A (en) *	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
YU18596A (sh) *	1995-03-31	1998-07-10	Eli Lilly And Company	Analogne formulacije monomernog insulina
WO1997002043A1 (en) *	1995-06-30	1997-01-23	Novo Nordisk A/S	Prevention of a disease having the characteristics of diabetes
RU2182015C2 (ru) *	1996-06-20	2002-05-10	Ново Нордиск А/С	ПРЕПАРАТ ИНСУЛИНА, СОДЕРЖАЩИЙ NaCl, ПАРЕНТЕРАЛЬНАЯ ГОТОВАЯ ФОРМА, СПОСОБ ПОВЫШЕНИЯ ХИМИЧЕСКОЙ СТАБИЛЬНОСТИ ПРЕПАРАТА ИНСУЛИНА
UA72427C2 (en) *	1996-06-20	2005-03-15	Novo Nordisk As	Water-soluble insulin preparation containing mannite, method for manufacturing composition containing soluble insulin or crystalline insulin
ZA984697B (en) *	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
KR20010024556A (ko)	1997-10-24	2001-03-26	피터 지. 스트링거	불용성 인슐린 조성물
US6531448B1 (en) *	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
EP1044016B1 (en) *	1998-01-09	2005-03-16	Novo Nordisk A/S	Stabilised insulin compositions
US6211144B1 (en)	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
WO2000023099A1 (en) *	1998-10-16	2000-04-27	Novo Nordisk A/S	Insulin preparations for pulmonary delivery containing menthol
PT1121144E (pt) *	1998-10-16	2002-11-29	Novo Nordisk As	Preparados de insulina concentrada estavel para administracao pulmonar
US6635617B1 (en)	1998-10-16	2003-10-21	Novo Nordisk A/S	Insulin preparations for pulmonary delivery containing menthol
JP2002529514A (ja) *	1998-11-18	2002-09-10	ノボノルディスクアクティーゼルスカブ	フェノール及びクレゾールを要さない安定なインスリン水性調製物
US6489292B1 (en)	1998-11-18	2002-12-03	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) *	1999-01-06	2004-10-28	Dimarchi Richard Dennis	Method for administering monomeric insulin
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
US6734162B2 (en)	2000-01-24	2004-05-11	Minimed Inc.	Mixed buffer system for stabilizing polypeptide formulations
US7227033B2 (en)	2002-01-09	2007-06-05	Emisphere Technologies, Inc.	Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
ATE429925T1 (de) *	2000-07-31	2009-05-15	Univ Bar Ilan	Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20040037828A1 (en)	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en)	2001-06-28	2004-05-18	Metronic Minimed, Inc.	Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
RU2202365C2 (ru) *	2001-07-20	2003-04-20	Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН	Способ приготовления быстродействующего раствора инсулина для инъекций
US20040005999A1 (en) *	2002-03-07	2004-01-08	Andreasen Kasper Huus	Polyamino acid-based particle insulin preparation
US20030211976A1 (en) *	2002-03-07	2003-11-13	Andreasen Kasper Huus	Polyamino acid-based particle insulin formulation
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) *	2003-03-13	2006-11-16	Novo Nordisk A/S	Novel NPH insulin preparations
EA014887B1 (ru)	2003-06-17	2011-02-28	Сембайосиз Джинетикс Инк.	Способ экспрессии инсулина в семенах растения, способ получения семян растений, содержащих инсулин, и растения, способные производить семена, содержащие инсулин
US20060241019A1 (en) *	2003-07-25	2006-10-26	Bridon Dominique P	Long lasting insulin derivatives and methods thereof
AU2005209199B2 (en) *	2004-01-16	2008-09-11	Biodel Inc.	Sublingual drug delivery device
US20080085298A1 (en) *	2004-03-12	2008-04-10	Biodel, Inc.	Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) *	2004-03-12	2008-04-24	Biodel, Inc.	Rapid mucosal gel or film insulin compositions
CN102001962B (zh)	2004-05-06	2013-04-03	爱密斯菲尔科技公司	N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
EP1745004B8 (en) *	2004-05-14	2016-07-27	Emisphere Technologies, Inc.	Aryl ketone compounds and compositions for delivering active agents
WO2005115341A2 (en) *	2004-05-27	2005-12-08	Advanced Bionutrition Corporation	Microparticles for oral delivery
US7872095B2 (en)	2004-07-19	2011-01-18	Biocon Limited	Insulin-oligomer conjugates, formulations and uses thereof
CN101014360A (zh)	2004-08-03	2007-08-08	埃米斯菲尔技术公司	抗糖尿病口服胰岛素－双胍组合物
US7597884B2 (en)	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
US20060078622A1 (en) *	2004-08-13	2006-04-13	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
CA2581798A1 (en) *	2004-10-05	2006-04-13	Petter Lybeck	A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
JP4874989B2 (ja)	2004-11-22	2012-02-15	ノヴォノルディスクアー／エス	可溶性で安定なインスリン含有調合物
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
EP1862174A1 (en) *	2005-03-02	2007-12-05	Ajinomoto Co., Inc.	Inhibitor for insulin polymer formation
ZA200802546B (en)	2005-08-29	2009-10-28	Healor Ltd	Methods and compositions for prvention and treatment of diabetic and aged skin
KR20080049128A (ko)	2005-09-19	2008-06-03	에미스페어 테크놀로지스, 인코포레이티드	Ｎ-(5-클로로살리실로일)-8-아미노카프릴산 이나트륨염의결정형
US7713929B2 (en) *	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US8084420B2 (en)	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
WO2007096332A1 (en) *	2006-02-21	2007-08-30	Novo Nordisk A/S	Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007121318A2 (en)	2006-04-12	2007-10-25	Emisphere Technologies, Inc.	Formulations for delivering insulin
US7718609B2 (en)	2006-04-12	2010-05-18	Biodel Inc.	Rapid acting and long acting insulin combination formulations
EP2074140B8 (en)	2006-10-04	2015-10-28	Case Western Reserve University	Fibrillation-resistant insulin and insulin analogues
PL3050568T3 (pl)	2007-03-13	2021-06-14	Jds Therapeutics, Llc	Sposoby i kompozycje do przedłużonego uwalniania chromu
US8466199B2 (en) *	2007-03-21	2013-06-18	Emisphere Technologies, Inc.	Allyloxy and alkyloxy benzoic acid delivery agents
WO2008132229A2 (en) *	2007-04-30	2008-11-06	Novo Nordisk A/S	Highly concentrated insulin solutions and compositions
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CN101939023B (zh)	2007-10-16	2016-08-03	百康有限公司	可经口给药的固体药物组合物及其方法
AU2008318423B2 (en)	2007-11-02	2013-12-05	Emisphere Technologies, Inc.	Method of treating vitamin B12 deficiency
BRPI0916560A2 (pt)	2008-07-31	2015-11-10	Univ Case Western Reserve	análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
CN102209541B (zh)	2008-09-08	2016-05-18	小利兰·斯坦福大学托管委员会	醛脱氢酶活性调节剂和其使用方法
PT2349324T (pt)	2008-10-17	2017-12-06	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
US8389522B2 (en)	2008-10-28	2013-03-05	The Board Of Trustees Of The Leland Stanford Junior University	Modulators of aldehyde dehydrogenase and methods of use thereof
EP2391218B1 (en)	2009-01-28	2020-03-18	Smartcells, Inc.	Conjugate based systems for controlled drug delivery
JP2012516340A (ja)	2009-01-28	2012-07-19	スマートセルズ・インコーポレイテツド	合成コンジュゲートおよびその使用
CN102316892B (zh)	2009-02-12	2014-06-04	西马生物医学计划公司	心肌营养素-1用于治疗代谢病的用途
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
EP2408808A4 (en)	2009-03-20	2015-05-06	Smartcells Inc	TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
WO2011083481A2 (en)	2010-01-11	2011-07-14	Healor Ltd.	Method for treatment of inflammatory disease and disorder
CA2996757A1 (en) *	2010-02-24	2011-09-01	Emisphere Technologies, Inc.	Oral b12 therapy
RS55378B1 (sr)	2010-08-30	2017-03-31	Sanofi Aventis Deutschland	Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
EP2621911A1 (en)	2010-09-30	2013-08-07	Solvay Sa	Derivative of epichlorohydrin of natural origin
WO2012115641A1 (en)	2011-02-23	2012-08-30	Elona Biotechnologies	Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
AU2012223282B2 (en)	2011-03-01	2017-02-02	Nutrition 21, Llc	Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2012149106A1 (en)	2011-04-29	2012-11-01	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HRP20151068T1 (hr)	2011-08-29	2016-01-01	Sanofi-Aventis Deutschland Gmbh	Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9908925B2 (en)	2011-10-27	2018-03-06	Case Western Reserve University	Ultra-concentrated rapid-acting insulin analogue formulations
US10159735B2 (en) *	2012-06-26	2018-12-25	The Curators Of The University Of Missouri	Photocleavable drug conjugates
EP2877200B1 (en)	2012-07-17	2019-05-08	Case Western Reserve University	O-linked carbohydrate-modified insulin analogues
JP6322642B2 (ja)	2012-11-13	2018-05-09	アドシア	置換されたアニオン性化合物を含有する速効型インスリン製剤
EP2925345B1 (en)	2012-12-03	2018-09-05	Merck Sharp & Dohme Corp.	Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CA2889165A1 (en)	2012-12-19	2014-06-26	Wockhardt Limited	A stable aqueous composition comprising human insulin or an analogue or derivative thereof
WO2014102623A1 (en)	2012-12-26	2014-07-03	Wockhardt Limited	Pharmaceutical composition
WO2014160185A2 (en)	2013-03-14	2014-10-02	The Board Of Trustees Of The Leland Stanford Junior University	Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
AR098168A1 (es)	2013-10-25	2016-05-04	Sanofi Sa	Formulación estable de insulina glulisina
US10124040B2 (en)	2014-08-26	2018-11-13	Merck Sharp & Dohme Corp.	Method for preparing crystalline insulin or insulin analog compositions
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
MX2018009748A (es)	2016-02-11	2019-02-07	Nutrition 21 Llc	Composiciones que contienen cromo para mejorar la salud y el estado físico.
IL270975B2 (en)	2017-06-01	2024-02-01	Lilly Co Eli	Fast-acting insulin preparations
WO2019125878A1 (en)	2017-12-18	2019-06-27	Merck Sharp & Dohme Corp.	Conjugate based systems for controlled insulin delivery
EP3740212A4 (en)	2017-12-18	2021-10-27	Merck Sharp & Dohme Corp.	CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
KR20220115927A (ko)	2019-10-25	2022-08-19	세르카코르 래버러토리즈, 인크.	지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법
KR20220161422A (ko)	2020-03-31	2022-12-06	프로토머 테크놀로지스 인크.	비시날 디올에 대한 선택적인 반응을 위한 접합체
JP2024500284A (ja)	2020-11-19	2024-01-09	プロトマー・テクノロジーズ・インコーポレイテッド	芳香族ホウ素含有化合物及びインスリン類似体
AU2023272483A1 (en)	2022-05-18	2024-12-12	Protomer Technologies Inc.	Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3060093A (en) *	1957-07-18	1962-10-23	Nordisk Insulinlab	Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) *	1979-08-22	1981-03-12	Hoechst Ag, 6000 Frankfurt	Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (sv) *	1982-02-05	1989-09-11	Novo Industri As	Förfarande för framställning av en för infusionsändamål avsedd stabili serad insulinlösning, som har en förhöjd zinkhalt
US4608634A (en) *	1982-02-22	1986-08-26	Texas Instruments Incorporated	Microcomputer with offset in store-accumulator operations
DK347086D0 (da) *	1986-07-21	1986-07-21	Novo Industri As	Novel peptides
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
DE3717370A1 (de) *	1987-05-22	1988-12-01	Hoechst Ag	Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE93238T1 (de) *	1988-07-20	1993-09-15	Novo Nordisk As	Menschliche insulinanalage und zubereitungen daraus.
JPH04502465A (ja) *	1988-12-23	1992-05-07	ノボ　ノルディスク　アクティーゼルスカブ	ヒトインシュリン類似物質
IL93282A (en) *	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
DE69416409T2 (de) *	1993-06-21	1999-09-16	Novo Nordisk A/S, Bagsvaerd	Asp-b28-insulinkristalle
HU217684B (hu) *	1993-09-17	2000-03-28	Novo Nordisk A/S	Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US5504188A (en) *	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5597893A (en) *	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
YU18596A (sh) *	1995-03-31	1998-07-10	Eli Lilly And Company	Analogne formulacije monomernog insulina

1994
- 1994-06-16 US US08/260,634 patent/US5474978A/en not_active Expired - Lifetime
- 1994-06-24 TW TW083105767A patent/TW421596B/zh not_active IP Right Cessation
1995
- 1995-06-12 CA CA002151560A patent/CA2151560C/en not_active Expired - Lifetime
- 1995-06-13 HU HU9501716A patent/HU227240B1/hu unknown
- 1995-06-13 RS YUP-396/95A patent/RS49577B/sr unknown
- 1995-06-14 SI SI9500200A patent/SI9500200A/sl not_active IP Right Cessation
- 1995-06-14 CH CH01763/95A patent/CH689250A5/de not_active IP Right Cessation
- 1995-06-14 CO CO95026235A patent/CO4410203A1/es unknown
- 1995-06-14 LU LU88626A patent/LU88626A1/fr unknown
- 1995-06-14 NZ NZ272359A patent/NZ272359A/en not_active IP Right Cessation
- 1995-06-14 MY MYPI95001593A patent/MY115631A/en unknown
- 1995-06-14 GB GB9512038A patent/GB2291427B/en not_active Expired - Lifetime
- 1995-06-14 PE PE1995271263A patent/PE19496A1/es not_active IP Right Cessation
- 1995-06-14 IT IT95MI001278A patent/IT1276723B1/it active IP Right Grant
- 1995-06-14 UA UA95062794A patent/UA26874C2/uk unknown
- 1995-06-14 IL IL11415195A patent/IL114151A/xx not_active IP Right Cessation
- 1995-06-14 CH CH02040/98A patent/CH689935A5/de not_active IP Right Cessation
- 1995-06-14 CZ CZ19951542A patent/CZ287484B6/cs not_active IP Right Cessation
- 1995-06-14 SE SE9502167A patent/SE509052C2/sv not_active IP Right Cessation
- 1995-06-14 PL PL95309098A patent/PL181310B1/pl unknown
- 1995-06-14 CN CN95106568A patent/CN1105576C/zh not_active Ceased
- 1995-06-14 RU RU95110109/04A patent/RU2152399C2/ru active
- 1995-06-14 BR BR9502795A patent/BR9502795A/pt not_active IP Right Cessation
- 1995-06-14 GR GR950100229A patent/GR1003004B/el not_active IP Right Cessation
- 1995-06-14 NO NO19952357A patent/NO322128B1/no not_active IP Right Cessation
- 1995-06-14 KR KR1019950015782A patent/KR100382326B1/ko not_active Expired - Lifetime
- 1995-06-14 IE IE950436A patent/IE68853B1/en not_active IP Right Cessation
- 1995-06-14 DK DK199500677A patent/DK173015B1/da not_active IP Right Cessation
- 1995-06-14 NL NL1000566A patent/NL1000566C2/xx not_active IP Right Cessation
- 1995-06-14 PT PT101722A patent/PT101722B/pt not_active IP Right Cessation
- 1995-06-14 BE BE9500526A patent/BE1009408A5/fr active
- 1995-06-14 AT AT0101695A patent/AT408720B/de not_active IP Right Cessation
- 1995-06-14 JP JP14732195A patent/JP3171541B2/ja not_active Expired - Lifetime
- 1995-06-14 DE DE19521720A patent/DE19521720B4/de not_active Expired - Lifetime
- 1995-06-14 FR FR9507094A patent/FR2721214B1/fr not_active Expired - Lifetime
- 1995-06-14 RO RO95-01140A patent/RO113530B1/ro unknown
- 1995-06-14 ES ES09501195A patent/ES2091727B1/es not_active Expired - Fee Related
- 1995-06-14 FI FI952931A patent/FI118207B/sv not_active IP Right Cessation
- 1995-06-14 ZA ZA9504943A patent/ZA954943B/xx unknown
1997
- 1997-01-09 FR FR9700156A patent/FR2741078B1/fr not_active Expired - Lifetime
2001
- 2001-01-18 JP JP2001010342A patent/JP2001199899A/ja active Pending

Also Published As

Publication number	Publication date
IE950436A1 (en)	1995-12-27
NO952357D0 (no)	1995-06-14
DE19521720B4 (de)	2009-09-03
HK1015138A1 (en)	1999-10-08
CZ154295A3 (en)	1996-02-14
DK173015B1 (da)	1999-11-15
IE68853B1 (en)	1996-07-24
CA2151560C (en)	2000-05-09
CZ287484B6 (en)	2000-12-13
GB9512038D0 (en)	1995-08-09
BR9502795A (pt)	1996-03-12
SE509052C2 (sv)	1998-11-30
GR1003004B (el)	1998-11-05
FR2721214B1 (fr)	1997-09-26
NO952357L (no)	1995-12-18
IL114151A0 (en)	1995-10-31
ES2091727B1 (es)	1998-02-01
GB2291427A (en)	1996-01-24
PL309098A1 (en)	1995-12-27
FI118207B (sv)	2007-08-31
NZ272359A (en)	1996-10-28
JP2001199899A (ja)	2001-07-24
PL181310B1 (pl)	2001-07-31
CN1105576C (zh)	2003-04-16
LU88626A1 (fr)	1996-02-01
RU95110109A (ru)	1997-05-10
JP3171541B2 (ja)	2001-05-28
NL1000566C2 (nl)	1996-12-03
FR2721214A1 (fr)	1995-12-22
RS49577B (sr)	2007-04-10
CH689250A5 (de)	1999-01-15
SI9500200A (en)	1996-02-29
KR960000924A (ko)	1996-01-25
HU227240B1 (en)	2010-12-28
TW421596B (en)	2001-02-11
PT101722B (pt)	1997-02-28
DK67795A (da)	1995-12-17
KR100382326B1 (ko)	2003-07-07
ITMI951278A0 (it)	1995-06-14
GR950100229A (en)	1996-02-29
CA2151560A1 (en)	1995-12-17
BE1009408A5 (fr)	1997-03-04
NO322128B1 (no)	2006-08-21
HUT73186A (en)	1996-06-28
YU39695A (sh)	1997-08-22
AU2168095A (en)	1996-01-04
HU9501716D0 (en)	1995-08-28
GB2291427B (en)	1998-09-16
AU694501B2 (en)	1998-07-23
CN1122248A (zh)	1996-05-15
FR2741078B1 (fr)	1998-08-07
CO4410203A1 (es)	1997-01-09
DE19521720A1 (de)	1995-12-21
RU2152399C2 (ru)	2000-07-10
JPH083067A (ja)	1996-01-09
SE9502167D0 (sv)	1995-06-14
NL1000566A1 (nl)	1995-12-18
ES2091727A1 (es)	1996-11-01
AT408720B (de)	2002-02-25
US5474978A (en)	1995-12-12
IT1276723B1 (it)	1997-11-03
CH689935A5 (de)	2000-02-15
ITMI951278A1 (it)	1996-12-14
FR2741078A1 (fr)	1997-05-16
IL114151A (en)	2000-09-28
ATA101695A (de)	2001-07-15
RO113530B1 (ro)	1998-08-28
UA26874C2 (uk)	1999-12-29
PT101722A (pt)	1995-12-29
MY115631A (en)	2003-08-30
ZA954943B (en)	1997-09-14
PE19496A1 (es)	1996-06-01
FI952931A0 (sv)	1995-06-14
FI952931L (sv)	1995-12-17

Publication	Publication Date	Title
SE9502167L (sv)	1995-12-17	Insulinanalog-kompositioner
SE9502168L (sv)	1995-12-17	Insulinanalog-kompositioner
ATE247666T1 (de)	2003-09-15	Wasserlöslische prodrugs von 2,6- diisopropylphenol-analoga
SI0801564T1 (en)	2002-08-31	Use of nebivolol as an anti-atherogenic
BG103740A (en)	2000-05-31	Phytostyrene composition for the prevention of the alzheimer's disease
UA39158C2 (uk)	2001-06-15	Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
AP2000001947A0 (en)	2000-12-31	Novel crystalline forms of an antiviral benzidazole compound.
BR9507758A (pt)	1997-09-23	Fração de copolímero-1 e composição para o tratamento de esclerose múltipla
EP0339237A3 (en)	1991-01-09	Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
BG102215A (en)	1998-09-30	Compounds and pharmaceutical compositions containing them
BG103429A (en)	2000-04-28	Methods and compositions for neurone growth stimulation
BR9906796A (pt)	2000-11-14	Método para a administração de análogos de insulina monoméricos
BR9910573A (pt)	2001-01-16	Compostos antipicornavirais, preparação e uso dos mesmos
EP0911331A3 (en)	2000-01-19	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
MY120976A (en)	2005-12-30	2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
BR9911917A (pt)	2001-03-27	Composições compreendendo análogos de gaba e cafeìna
DE69814109D1 (de)	2003-06-05	1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
IL126235A (en)	2003-02-12	Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
BRPI0408889A (pt)	2006-04-11	uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
ATE272648T1 (de)	2004-08-15	Glycokonjugate von 20(s)-camptothecin
Przuntek et al.	1985	The protective effect of 1-tert. butyl-4, 4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
AR059965A2 (es)	2008-05-14	Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
IT9020020A0 (it)	1990-04-12	"n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
AU4630599A (en)	2000-01-24	Perfume composition
DE69327693D1 (de)	2000-03-02	Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen

Legal Events

Date	Code	Title	Description
2015-08-04	NUG	Patent has lapsed